Company intelligence / Profile preview

Greenitio

Ownership: Private
Development stage: Commercial

Overview

Greenitio has developed two proprietary market-ready biopolymer ingredients—CHITOBE and CHITOBELA—that can directly replace microplastics in skin and hair care formulations. These have demonstrated functional benefits such as antimicrobial activity, antioxidant properties, moisturization, improved conditioning effects in hair care products, and SPF enhancement. Comparative studies show superior performance to conventional alternatives; further clinical trials are ongoing as of early 2024 with product launches targeted by July 2024.

Modalities: BiopolymerNatural polymer
Industry: Non-Drug Biotech

Partnerships

Collaborates with several large multinational brands in cosmetics and personal care sectors; specific partners not disclosed

Beyond the preview

Go deeper on Greenitio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Greenitio.

Explore the full profile